Pooled trial shows Spiriva (Boehringer) effective for Asthma

Pooled Phase III data from the replicate PrimoTinA-asthma studies provide further evidence for Spiriva (tiotropium bromide), from Boehringer, delivered via the Respimat inhaler as a possible add-on treatment for severe persistent Asthma. Data presented at CHEST show that in adult Asthma patients who remain symptomatic despite treatment with at least inhaled corticosteroids (ICS)/long-acting beta-2 agonists (LABA), tiotropium delivered via the Respimat inhaler reduced the risk of severe Asthma exacerbations and any Asthma exacerbation.

These results add to data from the ongoing Phase III trial program that has previously shown positive results for tiotropium in severe Asthma patients who remained symptomatic despite treatment with at least ICS/LABA. A pooled analysis of adverse event (AE) data from the PrimoTinA-asthma studies shows a lower percentage of patients in the tiotropium-treated group (73.5 percent) reported AEs versus placebo (80.3 percent) patients.